“New Clinical Study Further Validates Use of ReceptivaDx” – Business Wire

Business Wire helped CiceroDx, Inc. to announce the publication of a new study that demonstrates the effectiveness of treatment in unexplained infertility patients with abnormal endometrial BCL6 expression. The study supports the growing empirical evidence showing the relationship of BCL6 expression with endometrial inflammation and suspected endometriosis.

The results showed a significant increase in the clinical pregnancy rate and live birth rate for treatments of patients who tested positive for BCL6. For these patients, the miscarriage rate also saw a significant decrease.

The study gives thousands of women with unexplained infertility new hope and a new pathway to success, potentially saving thousands of dollars on IVF cycles by identifying patients in advance with low likelihood of IVF success if left untreated.

To learn more about the study and to read the full article on Business Wire, click here.
https://www.businesswire.com/news/home/20190219005108/en/

Bruce Lessey, M.D., Ph.D. – Scientific Advisor
Lessey’s Corner

The ReceptivaDxTM Test was developed by CiceroDx in conjunction with Pathology Consultants, Inc. of Greenville, SC. Pathology Consultants, Inc. is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies. Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.


Copyright © 2019 ReceptivaDx™ | All Rights Reserved